Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

474 RANITIDINE
(1989): Grant SM+, Drugs 37, 801
(1984): Khandheria BK, JAMA 253, 3252
(1983): Picardo M+, Contact Dermatitis 4, 327
Vasculitis
(1988): Haboubi N+, BMJ 296, 897
Xerosis
Hair
Hair – alopecia
(1995): Shelley WB+, Cutis 55, 148 (observation)
Other
Anaphylactoid reactions/Anaphylaxis
(2007): Thurot-Guillou C+, Eur J Dermatol A(2), 170
(2006): Demirkan K+, J Investig Allergol Clin Immunol 16(3), 203
(2 cases)
(2003): Kaneko K+, JAnesth17(3), 199
(1993): Lazaro M+, Allergy 48, 385
(1993): Powell JA+, Anaesth Intensive Care 21, 702
Gynecomastia (>1%)
(1994): Garcia-Rodriguez LA+, BMJ 308, 503
(1984): Bianchi Porro G+, It J Gastroenterol (Italian) 16, 56
(1982): Tosi S+, Lancet 2, 160
Hepatotoxicity
(2001): Fisher AA+, Drug Saf 24(1), 39
Hypersensitivity
(2006): Oldfield V+, BioDrugs 20(3), 197
(1996): Gonzalo-Garijo MA+, Allergy 51, 659
Injection-site burning
Injection-site pain
Myalgia/Myositis/Myopathy/Myotoxicity
Porphyria
(1988): Bhadoria DP+, J Assoc Physicians India 36, 295
(1988): Pratap D+, J Assoc Physicians India 36, 237
(1988): Tripathi SK, J Assoc Physicians India 36, 680
Pseudolymphoma
(1995): Magro CM+, JAmAcadDermatol32, 419
(1988): Kardaun SH+, Br J Dermatol 118(4), 545
RANOLAZINE
Trade name: Ranexa (CV Therapeutics)
Indications: Angina
Category: Anti-ischemic; Fatty acid oxidation inhibitor
Half-life: ~2 hours
Clinically important, potentially hazardous interactions
with: cyclosporine, diltiazem, grapefruit, ketoconazole, ritonavir,
verapamil
Note: Ranolazine is contraindicated in patients with existing QTc
prolongation, and in patients with liver disease
Skin
Peripheral edema
Mucosal
Xerostomia (